Tumor-targeting Nanomaterials Based on Metal-organic Frameworks Mediate Tumor Immunotherapy by Promoting Cuproptosis and Pyroptosis in Hepatocellular Carcinoma Cells
Materials Today Bio,
Год журнала:
2025,
Номер
unknown, С. 101745 - 101745
Опубликована: Апрель 1, 2025
Язык: Английский
NIR-activatable proenzyme DSF/CuS@M for synergistic in situ chemotherapy/CDT/PTT/cuproptosis-based antitumor therapy
Lushuang Xu,
Qinyue Chen,
Yangwei Qian
и другие.
Chemical Engineering Journal,
Год журнала:
2025,
Номер
unknown, С. 161733 - 161733
Опубликована: Март 1, 2025
Язык: Английский
An up‐To‐Date Review of Elesclomol and Its Nano‐Formulations in Cancer Therapy
Cancer Reports,
Год журнала:
2025,
Номер
8(4)
Опубликована: Апрель 1, 2025
ABSTRACT
Background
Elesclomol
(ES)
is
a
promising
anticancer
compound
that
exerts
its
effects
through
multiple
mechanisms.
It
acts
as
copper
(Cu(II))
ionophore,
forming
an
ES–Cu
complex
within
cancer
cells
and
inducing
novel
form
of
cell
death
called
cuproptosis.
Aim
To
provide
up‐to‐date
review
on
elesclomol
nano‐formulations
with
particular
focus
therapy.
Sources
Literature
was
collected
by
manually
searching
in
Pubmed,
Google
Scholar,
clinicaltrials.gov
March
2025.
Content
This
provides
overview
the
discovery
development
ES
molecule,
including
physicochemical
properties.
New
insights
into
intracellular
interactions
mechanisms
transportation
are
then
explained.
The
recent
clinical
outcomes
therapy,
both
monotherapy
combination
paclitaxel
or
carboplatin,
summarized.
While
initial
trials
showed
promise,
more
studies
focusing
preclinical
investigations
complex.
Nanomedicine‐based
formulations
have
emerged
strategy
to
enhance
delivery
well
therapeutic
effects,
several
nanomedicines
currently
under
development.
nanoparticle
strategies
discussed.
comprehensive
advancements
study,
mechanism
action,
progress,
potential
nanomedicine‐based
approaches
improve
efficacy
treatment.
Язык: Английский
An exosome-based nanoplatform for siRNA delivery combined with starvation therapy promotes tumor cell death through autophagy, overcoming refractory KRAS-mutated tumors and restoring cetuximab chemosensitivity
Materials Today Bio,
Год журнала:
2025,
Номер
unknown, С. 101732 - 101732
Опубликована: Апрель 1, 2025
Язык: Английский